S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
Cellular Oncology · 2025
DOI: 10.1007/s13402-025-01087-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Xianwei Zhou und 15 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing D…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, STAT3 Transcription Factor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing Uni…
- MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nan…
- Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Department of Hepatobiliary Surgery, Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui M…
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Affiliated Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, 210008, China.
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, China.
Zitieren
APA
Zhou, X., Qiao, C., Chu, X., Yang, Y., Man, H., Liu, J., Li, Y., Xu, Z., Li, H., Shan, X., Lian, Z., Lu, Y., Wang, W., Yu, D., Sun, X., & Li, B. (2025). S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway. Cellular Oncology. https://doi.org/10.1007/s13402-025-01087-0
Vancouver
Zhou X, Qiao C, Chu X, Yang Y, Man H, Liu J, et al. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway. Cellular Oncology. 2025. doi:10.1007/s13402-025-01087-0
BibTeX
@article{Zhou2025,
author = {Zhou, Xianwei and Qiao, Chu and Chu, Xuehui and Yang, Yajing and Man, Haoran and Liu, Jingxin and Li, Yunzheng and Xu, Zhu and Li, Huan and Shan, Xiaodong and Lian, Zaowu and Lu, Yanjun and Wang, Weihong and Yu, Decai and Sun, Xitai and Li, Binghua},
title = {S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway},
journal = {Cellular Oncology},
year = {2025},
doi = {10.1007/s13402-025-01087-0}
}
EUVIMED